1)Touitou V, Bodaghi B, Cassoux N et al:Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 140:949-952, 2005
2)Kasahara A, Hiraide A, Tomita N et al:Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 39:1106-1109, 2004
3)Carella C, Mazziotti G, Amato G et al:Interferon-α-related thyroid disease:pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 89:3656-3661, 2004
4)Bohbot NL, Young J, Orgiazzi J et al:Interferon-α-induced hyperthyroidism:a three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol 154:367-372, 2006
5)Su DH, Chang Y-C, Liao S-L et al:Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 243:269-272, 2005
6)Villanueva RB, Brau N:Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid 12:737-738, 2002
7)Binaghi M, Lévy C, Douvin C et al:Severe thyroid ophthalmopathy related to interferon alpha therapy. J Fr Ophtalmol 25:412-415, 2002
8)DeMartelaere SL, Green MK, Shore JW:Exacerbation of Graves ophthalmopathy with interferon-alpha therapy. Ophthal Plast Reconstr Surg 23:319-321, 2007
9)Huet D, Entremont A, Hautecouverture M:Basedow's disease and interferon for hepatitis C. Recurrence as Basedow's ophthalmopathy after interferon reintroduction. Presse Med 29:82, 2000
10)Carella C, Mazziotti G, Morisco F et al:Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 86:1925-1929, 2001